Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01086423
Other study ID # 112584
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 1, 2010
Est. completion date November 19, 2010

Study information

Verified date April 2017
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the immunogenicity and reactogenicity of Infanrix-IPV/Hib™ vaccine when administered to healthy Chinese infants at 2, 3 and 4 or 3, 4 and 5 months of age.


Recruitment information / eligibility

Status Completed
Enrollment 985
Est. completion date November 19, 2010
Est. primary completion date November 19, 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Days to 90 Days
Eligibility Inclusion Criteria:

- A male or female infant between, and including, 60 and 90 days of age at the time of the first study visit.

- Born after a gestation period of 36 to 42 weeks, inclusive.

- Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol.

- Written informed consent obtained from the parent(s) or LAR(s) of the subject.

- Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

- Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.

- Child in care.

- Chronic administration of immunosuppressants or other immune-modifying drugs since birth.

- Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.

- Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during the study period, with the exception of hepatitis B vaccine.

- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.

- Evidence of previous or intercurrent diphtheria, tetanus, pertussis, poliomyelitis and/or Haemophilus influenzae type b (Hib) disease or vaccination.

- History of seizures or progressive neurological disease.

- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.

- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s).

- Major congenital defects or serious chronic illness.

The following condition is temporary or self-limiting and a subject may be vaccinated once the condition has resolved and no other exclusion criteria are met:

• Current febrile illness or axillary temperature > 37.0°C or other moderate to severe illness within 24 hours of study vaccine administration.

Study Design


Intervention

Biological:
Infanrix-IPV/Hib™
Intramuscular, three doses
Infanrix Hib™
Intramuscular, three doses
Poliorix™
Intramuscular, three doses

Locations

Country Name City State
China GSK Investigational Site Wuzhou Guangxi
China GSK Investigational Site Wuzhou Guangxi

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Antigens A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations greater than or equal to (=) 0.1 international units per milliliter (IU/mL). One month after the third vaccine dose (Month 3 or Month 4)
Primary Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP) Antigen A seroprotected subject was defined as a subject with anti-PRP antibody concentrations = 0.15 micrograms per milliliter (µg/mL). One month after the third vaccine dose (Month 3 or Month 4)
Primary Number of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3 Antigens A seroprotected subject was defined as a subject with anti-poliovirus (anti-polio) types 1, 2 and 3 antibody titres = the value of 8. One month after the third vaccine dose (Month 3 or Month 4)
Primary Number of Subjects With a Vaccine Response to Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) Antigens Vaccine response was defined as:
For PT and FHA response, antibody concentration = 20 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL) at post-vaccination.
For PRN response: for initially seronegative subjects [antibody concentration lower than (<) 5 EL.U/mL], post-vaccination antibody concentration = 20 EL.U/mL; for initially seropositive subjects (antibody concentration = 5 EL.U/mL), at least a 4-fold increase in antibody concentration from pre to post-vaccination.
One month after the third vaccine dose (Month 3 or Month 4)
Secondary Anti-D and Anti-T Antibody Concentrations Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL. Before the first dose (Month 0) and one month after the third dose of vaccination (Month 3 or Month 4)
Secondary Anti-PRP Antibody Concentrations Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in µg/mL. Before the first dose (Month 0) and one month after the third dose of study vaccine (Month 3 or Month 4)
Secondary Anti-polio Types 1, 2 and 3 Antibody Titers Antibody titers were presented as geometric mean titers (GMTs). Before the first dose (Month 0) and one month after the third dose of study vaccine (Month 3 or Month 4)
Secondary Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL. Before (Month 0) and one month after the third dose of study vaccine (Month 3 or Month 4)
Secondary Number of Subjects With Any Solicited Local Symptoms Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. During the 4-day (Days 0-3) post-vaccination period after each vaccine dose and across doses
Secondary Number of Subjects With Any Solicited General Symptoms Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever [defined as axillary temperature equal to or above 37.0 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade or relationship to study vaccination. During the 4-day (Days 0-3) post-vaccination period after each vaccine dose and across doses
Secondary Number of Subjects With Unsolicited Adverse Events (AEs) An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. During the 31-day (Days 0-30) post-vaccination period after any dose
Secondary Number of Subjects With Serious Adverse Events (SAEs) Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. During the entire study period (from Month 0 to Month 4/5)
See also
  Status Clinical Trial Phase
Completed NCT00352963 - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). Phase 3
Not yet recruiting NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj Phase 4
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Completed NCT02538211 - The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses N/A
Completed NCT01917357 - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Phase 3
Completed NCT01689324 - Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents Phase 1/Phase 2
Completed NCT01444781 - Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants Phase 3
Completed NCT01214889 - Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. Phase 3
Completed NCT00804284 - Database Surveillance Safety Study of PENTACEL® Vaccine N/A
Completed NCT00534833 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ Phase 3
Completed NCT00514709 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants Phase 3
Completed NCT00379977 - Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age Phase 3
Completed NCT00772369 - Retrospective Survey of Safety of Fourth Dose Pentacel® in Children Phase 4
Completed NCT00879827 - Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants Phase 3
Completed NCT01457495 - Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly Phase 2
Completed NCT01267058 - Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults Phase 3
Completed NCT02853929 - Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Phase 4
Completed NCT02858440 - A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia Phase 3
Recruiting NCT06049940 - Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population Phase 3
Completed NCT00385255 - Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults Phase 3